10. Myelodysplastic Syndrome: A Review of Current Care

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Kenneth H. Shain,
  2. Alan F. List and
  3. Rami S. Komrokji

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch10

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Shain, K. H., List, A. F. and Komrokji, R. S. (2011) Myelodysplastic Syndrome: A Review of Current Care, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch10

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • Myelodysplastic syndrome;
  • refractory anemia;
  • hypomethylation;
  • azacitidine;
  • decitabine;
  • lenalidomide


Myelodysplastic syndrome (MDS) is a heterogenous group of hematopoietic stem cell malignancies characterized by cytopenias, dysplastic hematopoiesis, increased proliferation, recurrent cytogenetic anomalies, and increased risk for transformation to acute myeloid leukemia. The expansion in our understanding of MDS biology has facilitated a new era in treatment of this disorder. This awareness has led to improved categorization of disease entities, as well as the development and validation of prognostic models for risk stratification. Moreover, progress has fostered the development of active disease-specific treatment modalities in addition to supportive care. Currently, three major treatment modalities are FDA-approved for the treatment of MDS. Within this chapter we will summarize the current classification system(s), prognostic stratification, and therapeutic modalities for this complex group of diseases including novel therapeutics.